<description>&lt;p class="MsoNormal"&gt;In this episode, I discuss corneal disease and treatments with &lt;strong&gt;David Eveleth, PhD,&lt;/strong&gt; the founder, president and CEO of Trefoil Therapeutics.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;em&gt;Brought to you by Alcon&lt;/em&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpFirst" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Welcome to another exciting episode of Eye Care insider &lt;strong&gt;&lt;em&gt;:14&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Intro David Eveleth, PhD &lt;strong&gt;&lt;em&gt;:47&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Eveleth’s background &lt;strong&gt;&lt;em&gt;1:05&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;What’s the treatment landscape now for corneal diseases and where are we falling short for patients? &lt;strong&gt;&lt;em&gt;2:59&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;The origins of Trefoil Therapeutics &lt;strong&gt;&lt;em&gt;7:27&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;FGF-1: Is it just important in the endothelium or is it also important in the epithelium? &lt;strong&gt;&lt;em&gt;11:47&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;What is your current lead investigational candidate? &lt;strong&gt;&lt;em&gt;14:01&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;When do you expect another read out of clinical data? &lt;strong&gt;&lt;em&gt;21:47&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;An adjunctive therapy with cataract surgery &lt;strong&gt;&lt;em&gt;18:27&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;What is the timeline of administration to patients? &lt;strong&gt;&lt;em&gt;19:24&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;When do you expect a readout of clinical data? &lt;strong&gt;&lt;em&gt;20:49&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Is it possible to use this also for the epithelium? &lt;strong&gt;&lt;em&gt;21:39&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;What are the most important challenges facing the ophthalmic industry? What is the most important factor to look for? &lt;strong&gt;&lt;em&gt;24:07&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;For more information about David Eveleth, PhD, and Trefoil Therapeutics, visit &lt;a href= "http://www.trefoiltherapeutics.com"&gt;www.trefoiltherapeutics.com&lt;/a&gt; &lt;strong&gt;&lt;em&gt;25:53&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Corneal disease can be fixed and better vision is possible &lt;strong&gt;&lt;em&gt;26:44&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpLast" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Thanks for listening &lt;strong&gt;&lt;em&gt;27:04&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoNormal"&gt;We’d love to hear from you! Send your comments/questions to Dr. Mali at &lt;a href= "mailto:eyecareinsider@healio.com"&gt;eyecareinsider@healio.com&lt;/a&gt;. Follow us on Twitter &lt;a href= "https://twitter.com/HRheuminations"&gt;@Healio_OSN&lt;/a&gt;. You can find follow Trefoil Therapeutics on Twitter @TrefoilThera.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;strong&gt;David Eveleth, PhD,&lt;/strong&gt; is the president and CEO of Trefoil Therapeutics.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;strong&gt;Disclosures:&lt;/strong&gt; Eveleth is the founder, CEO and shareholder of Trefoil Therapeutics. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.&lt;/p&gt;</description>

Eye Care Insider

Joshua Mali, MD

Corneal Rejuvenation with Trefoil Therapeutics

MAY 1, 202327 MIN
Eye Care Insider

Corneal Rejuvenation with Trefoil Therapeutics

MAY 1, 202327 MIN

Description

In this episode, I discuss corneal disease and treatments with David Eveleth, PhD, the founder, president and CEO of Trefoil Therapeutics.

Brought to you by Alcon

·       Welcome to another exciting episode of Eye Care insider :14

·       Intro David Eveleth, PhD :47

·       Eveleth’s background 1:05

·       What’s the treatment landscape now for corneal diseases and where are we falling short for patients? 2:59

·       The origins of Trefoil Therapeutics 7:27

·       FGF-1: Is it just important in the endothelium or is it also important in the epithelium? 11:47

·       What is your current lead investigational candidate? 14:01

·       When do you expect another read out of clinical data? 21:47

·       An adjunctive therapy with cataract surgery 18:27

·       What is the timeline of administration to patients? 19:24

·       When do you expect a readout of clinical data? 20:49

·       Is it possible to use this also for the epithelium? 21:39

·       What are the most important challenges facing the ophthalmic industry? What is the most important factor to look for? 24:07

·       For more information about David Eveleth, PhD, and Trefoil Therapeutics, visit www.trefoiltherapeutics.com 25:53

·       Corneal disease can be fixed and better vision is possible 26:44

·       Thanks for listening 27:04

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. You can find follow Trefoil Therapeutics on Twitter @TrefoilThera.

David Eveleth, PhD, is the president and CEO of Trefoil Therapeutics.

Disclosures: Eveleth is the founder, CEO and shareholder of Trefoil Therapeutics. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.